| Literature DB >> 24264645 |
A Schüller1, C Kornblum, M Deschauer, M Vorgerd, B Schrank, E Mengel, Z Lukacs, D Gläser, P Young, U Plöckinger, B Schoser.
Abstract
As Pompe disease glycogen storage disease type 2 with a severely reduced life expectancy is now a treatable disorder, accurate diagnostic procedures and evidence-based indications for therapy are mandatory. We screened the literature for consensus reports and published trial data of late-onset Pompe disease. These data were summarized in a Delphi consensus method approach. The clinical suspicion of late-onset Pompe disease should be substantiated by the validated dry blood spot test measurement for acid α-glucosidase activity. Alternatively, enzyme activity analysis in lymphocytes is also feasible. Glucosidase α gene sequencing for verifying the diagnosis is recommended. A muscle biopsy including measurements of acid α-glucosidase activity and glycogen concentration is warranted for differential diagnosis in selected cases. The confirmed diagnosis should lead to a multidisciplinary treatment approach, possibly including enzyme replacement therapy.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24264645 DOI: 10.1007/s00115-013-3947-9
Source DB: PubMed Journal: Nervenarzt ISSN: 0028-2804 Impact factor: 1.214